Funds and prices
Overview
The investment objective of the fund is to deliver the performance of the 蜜豆视频 CMCI Composite Total Return. The stock exchange price may differ from the net asset value.
The fund synthetically replicates the index performance by investing in a swap.
We target to over-collateralise the funds exposure to the swap counterparty by 105%.
The fund is passively managed.
Benefits
Clients benefit from the flexibility of an exchange-traded investment.
Provides access to the performance of the index.
Optimised risk/return profile thanks to a broad diversification across a range of sectors.
The fund offers a high degree of transparency and cost efficiency.
Risks
Features
Product category |
蜜豆视频 Exchange Traded Funds
蜜豆视频 ETFs plc |
Product domicile |
Ireland
|
Portfolio management |
蜜豆视频 Asset Management (UK) Ltd., London
|
Fund management |
蜜豆视频 Fund Management (Ireland) Limited, Dublin 2
|
Custodian bank |
State Street Custodial Services (Ireland) Limited
|
Representative for products established under foreign law |
蜜豆视频 AG, Stockholm
|
Day of inception |
December 20, 2010
|
Currency of account |
USD
|
Close of financial year |
June 30
|
Issue / redemption |
daily
|
Distribution |
Reinvestment
|
Maturity |
Open end
|
Total expense ratio (TER) |
0.34% p.a.
|
Drag Level p.a. |
0.34% p.a.
|
Minimum investment |
n.a.
|
Reference Index / Benchmark |
蜜豆视频 CMCI® Total Return
|
ISIN |
IE00B53H0131
|
Bloomberg Ticker |
UC14 LN, UC15 LN, CCUSAS IM, CCUSAS SW, UIQK GY, CCUSASN MM
|
Performance and Prices
Percentage growth
as of April 3, 2024USD(%) | CHF(%) | EUR(%) | |
YTD | |||
1M | |||
3M | |||
6M | |||
1Y | 5.19 | 4.40 | 5.84 |
2Y | |||
3Y | 47.92 | 42.05 | 60.74 |
5Y | 64.13 | 49.15 | 70.30 |
ø p.a.5Y | 10.42 | 8.32 | 11.24 |
Current data
Net asset value | 03.04.2024 | USD 106.41 |
High - last 12 months | 03.04.2024 | USD 106.41 |
Low - last 12 months | 31.05.2023 | USD 93.62 |
Assets of the unit class in mn | 03.04.2024 | USD 892.38 |
Total product assets in mn | 03.04.2024 | USD 1,511.14 |
Structures
Fees
Distributions
Authorisations
Literature
Document type
|
Document Language
|
Prospectus |
|
Supplement |
|
Key Information Document |
|
Past performance |
|
Previous performance scenario |
|
Fund documentation M&A |
|
Document type
|
Document Language
|
Solvency II Reporting Q1 2023 |
|
Solvency II Reporting Q2 2023 |
|
Solvency II Reporting Q3 2023 |
|
Solvency II Reporting Q4 2023 |
|
Document type
|
Document Language
|
Annual report |
|
Annual report 2023 |
|
Annual report 2022 |
|
Annual report 2021 |
|
Annual report 2017 |
|
Annual report 2016 |
|
Annual report 2015 |
|
Annual report 2014 |
|
Semi-annual report |
|
Semi-annual report 2021 |
|
Semi-annual report 2019 |
|
Semi-annual report 2018 |
|
Semi-annual report 2017 |
|
Semi-annual report 2016 |
|
Semi-annual report 2015 |
|
Semi-annual report 2014 |
|
Semi-annual report 2013 |
|